5NR Stock Chart & Stats
€27.88
-€0.12(-4.09%)
At close: 4:00 PM EST
€27.88
-€0.12(-4.09%)
Day’s Range― - ―
52-Week Range€3.89 - €47.86
Previous CloseN/A
Volume0.00
Average Volume (3M)127.00
Market Cap
€1.77B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume211
30 Day Avg. Volume127
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside97.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.2
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Strategic Collaboration With JanssenA global strategic collaboration with Janssen provides durable non-dilutive funding potential (upfront, milestones, royalties) and access to partner development and commercialization capabilities. Over months this materially de-risks clinical funding needs and strengthens pathway to market and payor access if trials progress.
Differentiated Lead Product PlatformNBTXR3 is a unique hafnium oxide nanoparticle designed to amplify radiotherapy and stimulate immune responses, offering a distinct mechanism versus standard oncology treatments. Platform breadth across multiple solid tumor indications supports durable clinical utility and repeatable development opportunities and partnership interest.
High Reported Gross Margin In 2025A reported 100% gross margin in 2025 indicates very low direct product costs or revenue mix skewed to high-margin partner/license receipts. If sustained with scaled sales or recurring partner payments, such margins support long-term operating leverage and faster path to profitability once R&D spend normalizes or commercialization ramps.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow shows the business is not self-funding development. Over a multi-month horizon this necessitates new financing or reliance on partner payments, increasing dilution or covenant risk and constraining ability to fund trials, manufacturing scale-up, or commercialization without external capital.
Negative Shareholders' Equity And Rising DebtNegative equity combined with meaningful debt growth weakens financial flexibility and raises refinancing and solvency risk. This structural capital weakness increases cost of capital, limits optionality for investments, and heightens creditor influence — all durable constraints on executing multi-indication clinical/commercial plans.
Volatile And Inconsistent Revenue HistoryLarge swings and an inconsistent revenue history indicate earnings are driven by lumpy partner payments or one-off items rather than stable product sales. This undermines predictability of cash inflows, complicates operational planning, partner negotiations, and long-term revenue modeling until recurring commercial revenues are demonstrated.
5NR FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €3.88 and its highest was €47.86 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.77B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 87 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in DE:5NR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
5NR Stock 12 Month Forecast
Average Price Target
€55.00
▲(97.27% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―
Options Prices
Currently, No data available
---